Professor of Radiopharmaceutical Chemistry
University Hospital Basel
Melpomeni Fani is Professor of Radiopharmaceutical Chemistry and the head of the division of Radiopharmaceutical Chemistry, Research and Development, at the University Hospital Basel, Switzerland. She is working on targeted radiopharmaceuticals for oncological diseases in preclinical and clinical settings. In the recent years, she has focused on the use of peptides in combination with different radioisotopes, to achieve all-in-one diagnosis and therapy, in what is known as theranostics. Her group is involved practically in the entire spectrum from peptide and chelation/bioconjugation chemistry, to radiochemistry, in vitro, in vivo and imaging studies (PET/CT and SPECT/CT), up to the clinical translation. Her achievements are linked with the development and first-in-man use of radiolabelled somatostatin receptor antagonists for imaging and therapy of neuroendocrine tumours, and with the advancements on 68Ga-radiopharmaceuticals, among others. She has authored 50+ scientific papers and 5 invited book chapters. She has given numerous invited lectures at scientific meetings and in advanced courses of pharmaceutical industry. She is in the editorial board of the Journal of Nuclear Medicine and Frontiers in Medicine and act as a reviewer for many journals and research funding organisations. She is member of the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Society of Molecular Imaging (ESMI) and an expert board member on (radio)peptides in various pharmaceutical companies. Prof. Fani is chemist by training and she holds a Master degree in Biochemistry (2000) and a PhD in Radiopharmacy (2003) from the University of Athens, Greece.